A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study

Sylvain Baruchel; Mark Bernstein; V. Michael Whitehead; Susan Devine; Beverly Bell; Ronald Dubowy; Holcombe Grier; Cynthia Kretschmar; Anne Marie Langevin; Teresa Vietti

doi:10.1007/BF00873802

A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study

Sylvain Baruchel, Mark Bernstein, V. Michael Whitehead, Susan Devine, Beverly Bell, Ronald Dubowy, Holcombe Grier, Cynthia Kretschmar, Anne Marie Langevin, Teresa Vietti

Division of Hematology-Oncology

Producción científica: Article › revisión exhaustiva

12 Citas (Scopus)

Resumen

Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M² daily for five days. Six patients including three patients with brain tumor had stable disease.

Idioma original	English (US)
Páginas (desde-hasta)	211-215
Número de páginas	5
Publicación	Investigational New Drugs
Volumen	13
N.º	3
DOI	https://doi.org/10.1007/BF00873802
Estado	Published - sept 1995

ASJC Scopus subject areas

Pharmacology (medical)
Oncology
Pharmacology

Acceder al documento

10.1007/BF00873802

Otros archivos y enlaces

Citar esto

@article{cf1888177d204694b9bed5d0d7f0bfc0,

title = "A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study",

abstract = "Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.",

keywords = "Phase I study, brain tumor, glutamine, glutathione",

author = "Sylvain Baruchel and Mark Bernstein and Whitehead, {V. Michael} and Susan Devine and Beverly Bell and Ronald Dubowy and Holcombe Grier and Cynthia Kretschmar and Langevin, {Anne Marie} and Teresa Vietti",

year = "1995",

month = sep,

doi = "10.1007/BF00873802",

language = "English (US)",

volume = "13",

pages = "211--215",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study

AU - Baruchel, Sylvain

AU - Bernstein, Mark

AU - Whitehead, V. Michael

AU - Devine, Susan

AU - Bell, Beverly

AU - Dubowy, Ronald

AU - Grier, Holcombe

AU - Kretschmar, Cynthia

AU - Langevin, Anne Marie

AU - Vietti, Teresa

PY - 1995/9

Y1 - 1995/9

N2 - Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.

AB - Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.

KW - Phase I study

KW - brain tumor

KW - glutamine

KW - glutathione

UR - http://www.scopus.com/inward/record.url?scp=0029553179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029553179&partnerID=8YFLogxK

U2 - 10.1007/BF00873802

DO - 10.1007/BF00873802

M3 - Article

C2 - 8729948

AN - SCOPUS:0029553179

SN - 0167-6997

VL - 13

SP - 211

EP - 215

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

A Phase I study of acivicin in refractory pediatric solid tumors - A Pediatric Oncology Group study

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto